KCM
UTHR icon

Kynam Capital Management’s United Therapeutics UTHR Stock Holding History

Kynam Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-67,588
Closed -$20M – 41
2025
Q3 		$20M Buy
+67,588
New +$22.7M 1.49% 18
2023
Q1 		– Sell
-100,000
Closed -$27.8M – 38
2022
Q4 		$27.8M Sell
100,000
-51,009
-34% -$12.9M 4.27% 7
2022
Q3 		$31.6M Buy
+151,009
New +$33.8M 6.66% 5

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $49B AUM 17.78% 1-Year Est. Return

Kynam Capital Management's UTHR Position: Q4 2025 in Review

Kynam Capital Management sold out of United Therapeutics (UTHR) in Q4 2025, closing a stake of 67,588 shares — an estimated $20M sold.

Kynam Capital Management first reported a position in UTHR in Q3 2022 and held it in 3 quarters. The position peaked at $31.6M in Q3 2022. 837 funds tracked by Wall St. Rank hold UTHR as of Q4 2025.

  • Kynam Capital Management reported no remaining United Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Kynam Capital Management sold 67,588 United Therapeutics shares in Q4 2025, an estimated $20M.
  • Kynam Capital Management first reported a position in United Therapeutics in Q3 2022 and held it in 3 quarters.
  • Kynam Capital Management's United Therapeutics position peaked at $31.6M in Q3 2022.
  • 837 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2025.

Based on Kynam Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.